These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 9853433)

  • 1. Substance-P antagonists: a new treatment for depression?
    Nutt D
    Lancet; 1998 Nov; 352(9141):1644-6. PubMed ID: 9853433
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical experience with substance P receptor (NK1) antagonists in depression.
    Ranga K; Krishnan R
    J Clin Psychiatry; 2002; 63 Suppl 11():25-9. PubMed ID: 12562140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can the placebo be the cure?
    Enserink M
    Science; 1999 Apr; 284(5412):238-40. PubMed ID: 10232967
    [No Abstract]   [Full Text] [Related]  

  • 4. Paxil (paroxetine) lifts depression, lowers associated anxiety symptoms.
    Adv Nurse Pract; 1997 Oct; 5(10):71. PubMed ID: 9459990
    [No Abstract]   [Full Text] [Related]  

  • 5. Addition of an NK1 receptor antagonist to an SSRI did not enhance the antidepressant effects of SSRI monotherapy: results from a randomized clinical trial in patients with major depressive disorder.
    Ball WA; Snavely DB; Hargreaves RJ; Szegedi A; Lines C; Reines SA
    Hum Psychopharmacol; 2014 Nov; 29(6):568-77. PubMed ID: 25330122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reward for persistence in substance P research.
    Wahlestedt C
    Science; 1998 Sep; 281(5383):1624-5. PubMed ID: 9767028
    [No Abstract]   [Full Text] [Related]  

  • 7. Use of paroxetine for the treatment of depression and anxiety disorders in the elderly: a review.
    Bourin M
    Hum Psychopharmacol; 2003 Apr; 18(3):185-90. PubMed ID: 12672169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spotlight on paroxetine in psychiatric disorders in adults.
    Wagstaff AJ; Cheer SM; Matheson AJ; Ormrod D; Goa KL
    CNS Drugs; 2002; 16(6):425-34. PubMed ID: 12027788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Substance P receptor antagonists--a new antidepressive and anxiolytic mechanism?].
    Lieb K; Fiebich BL; Berger M
    Nervenarzt; 2000 Sep; 71(9):758-61. PubMed ID: 11042872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct mechanism for antidepressant activity by blockade of central substance P receptors.
    Kramer MS; Cutler N; Feighner J; Shrivastava R; Carman J; Sramek JJ; Reines SA; Liu G; Snavely D; Wyatt-Knowles E; Hale JJ; Mills SG; MacCoss M; Swain CJ; Harrison T; Hill RG; Hefti F; Scolnick EM; Cascieri MA; Chicchi GG; Sadowski S; Williams AR; Hewson L; Smith D; Carlson EJ; Hargreaves RJ; Rupniak NM
    Science; 1998 Sep; 281(5383):1640-5. PubMed ID: 9733503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression.
    Fava M; Rosenbaum JF; Hoog SL; Tepner RG; Kopp JB; Nilsson ME
    J Affect Disord; 2000 Aug; 59(2):119-26. PubMed ID: 10837880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bupropion sustained release versus paroxetine for the treatment of depression in the elderly.
    Weihs KL; Settle EC; Batey SR; Houser TL; Donahue RM; Ascher JA
    J Clin Psychiatry; 2000 Mar; 61(3):196-202. PubMed ID: 10817105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The paroxetine controversy: lessons for ketamine trials.
    Zhang MW; Ho RC
    Lancet Psychiatry; 2015 Dec; 2(12):1057-8. PubMed ID: 26613847
    [No Abstract]   [Full Text] [Related]  

  • 14. Paroxetine and its uses in psychiatry.
    Bell C; Nutt D
    Hosp Med; 1999 May; 60(5):353-6. PubMed ID: 10396411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Substance P in depression.
    Salzman C
    Harv Ment Health Lett; 2001 Dec; 18(6):7. PubMed ID: 11751091
    [No Abstract]   [Full Text] [Related]  

  • 16. Successful paroxetine treatment of major depression in an adult form of metachromatic leukodystrophy with cognitive disturbances.
    Vella G; Loriedo C; Raccah R; Baldassarre P; Paolillo A
    Can J Psychiatry; 1998 Sep; 43(7):748-9. PubMed ID: 9773228
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease.
    Roose SP; Laghrissi-Thode F; Kennedy JS; Nelson JC; Bigger JT; Pollock BG; Gaffney A; Narayan M; Finkel MS; McCafferty J; Gergel I
    JAMA; 1998 Jan; 279(4):287-91. PubMed ID: 9450712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug therapy in treatment-resistant depression.
    Malhi GS; Farmer AE
    Br J Psychiatry; 1999 Oct; 175():390-1. PubMed ID: 10789311
    [No Abstract]   [Full Text] [Related]  

  • 19. Evaluation of double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients in menopause transition.
    Ushiroyama T; Ikeda A; Ueki M
    J Med; 2004; 35(1-6):151-62. PubMed ID: 18084873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paroxetine in the treatment of generalised anxiety disorder.
    Snyderman SH; Rynn MA; Bellew K; Rickels K
    Expert Opin Pharmacother; 2004 Aug; 5(8):1799-806. PubMed ID: 15264994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.